Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04608318
Title Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors German CLL Study Group
Age Groups: adult | senior
Covered Countries ITA | ESP | DEU | BEL | AUT

No variant requirements are available.